BioSpace News Archive

Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, announced the closing on April 20, 2020 of its previously announced underwritten public offering of 4,735,297 shares of its common stock at a price of $17.00 per share, which included the exercise in full by the underwr

Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of four oral and three poster presentations at the upcoming Digestive Disease Week (DDW) Annual Meeting. The presentations will take place during the DDW Annual Meeting being held virtually from May 2 to 5, 2020. Access to all accepted abstracts,

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release first quarter 2020 financial and operating results prior to market open on Tuesday, May 5, 2020. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time th

New energy deal puts Boston Scientific on pace to reach goal of carbon neutral manufacturing and operations

Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, launched its new Fundamentals UV/Vis standards and performance verification protocols for the Big Lunatic platform

Study examined the safety and tolerability of faster infusion rates and higher infusion volumes, as well as the feasibility of a new manual push administration method [21-April-2020] PHILADELPHIA , April 21, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that a clinical study examining faster infusion rates and higher volumes than curre

Audentes Therapeutics, Inc., an Astellas genetic medicines company, announced that it has appointed Julie Person as Senior Vice President, Human Resources.

Myovant Sciences, a healthcare company focused on redefining care for women’s health and prostate cancer, announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for once-daily, oral relugolix for the treatment of men with advanced prostate cancer.

Group sales revenue up 16.5%; order intake up 29.7%; underlying EBITDA margin 27.0%

Nanobiotix global development plan in head and neck cancer and immuno-oncology is moving forward and priorities remain unchanged with limited impact from the crisis